SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): March 3, 1998
___________________
SALIX PHARMACEUTICALS, LTD.
________________________________________________________________________________
(Exact name of registrant as specified in its charter)
BRITISH VIRGIN ISLANDS 000-23265 94-3267443
________________________________________________________________________________
(State or other (Commission File Number) (IRS Employer
jurisdiction of incorporation) Identification No.)
3600 WEST BAYSHORE ROAD, PALO ALTO, CALIFORNIA 94303
________________________________________________________________________________
(Address of principal executive offices) (Zip code)
(Registrant's telephone number, including area code): (650) 856-1500
SALIX HOLDINGS, LTD.
________________________________________________________________________________
(Former name, if changed since last report)
Item 5. Other Events.
On March 3, 1998, the Registrant amended its Memorandum and Articles of
Association of Incorporation by filing a Notice of Amendment of Memorandum and
Articles of Association (a copy of which is filed as an exhibit to this report
and is hereby incorporated by reference) with the Registry of Companies, British
Virgin Islands in order to change its name from Salix Holdings, Ltd. to Salix
Pharmaceuticals, Ltd. On March 24, 1998, the Registrant issued a news release
(a copy of which is filed as an exhibit to this report and is hereby
incorporated by reference) publicly announcing the change to the Registrant's
name.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
No financial statements or pro forma financial information are required to
be filed as a part of this report. The exhibits filed as part of this report are
listed in the Exhibit Index hereto.
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
SALIX PHARMACEUTICALS, LTD.
By: /s/ J. DAVID BOYLE
-----------------------
J. David Boyle
Chief Financial Officer
Dated: March 24, 1998
SALIX PHARMACEUTICALS, LTD.
EXHIBIT INDEX
Number and Description of Exhibit*
__________________________________
3.3 Notice of Amendment of Memorandum and Articles of Association, dated
March 3, 1998.
99.1. News release dated March 24, 1998 issued by Registrant
- ----------------
* Exhibits not listed are inapplicable.